SEP
HALO icon

Signature Equity Partners’s Halozyme HALO Stock Holding History

Signature Equity Partners’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.87K Sell
75
-45
-38% -$3.07K ﹤0.01% 953
2026
Q1 		$7.76K Buy
120
+118
+5,900% +$8.32K ﹤0.01% 858
2025
Q4 		$135 Buy
+2
New +$135 ﹤0.01% 1662

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Signature Equity Partners's HALO Position: Q2 2026 in Review

Signature Equity Partners reduced its Halozyme (HALO) stake by 38% in Q2 2026, selling an estimated $3.07K and leaving 75 shares worth $5.87K. The position accounts for ﹤0.01% of the portfolio, ranked #953.

Signature Equity Partners first reported a position in HALO in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.76K in Q1 2026. 674 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Signature Equity Partners held 75 shares of Halozyme worth $5.87K as of Q2 2026.
  • Signature Equity Partners sold 45 Halozyme shares in Q2 2026, an estimated $3.07K.
  • Halozyme made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #953 holding.
  • Signature Equity Partners first reported a position in Halozyme in Q4 2025 and has held it in 3 quarters since.
  • Signature Equity Partners's Halozyme position peaked at $7.76K in Q1 2026.
  • 674 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.